Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that that can be used for drug discovery and early-stage development.
ARENA PHARMA (ARNA): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
Original post
Zacks Investment Research
Beacon will focus on identifying and advancing molecules by leveraging the experience gained at Arena. The launch of Beacon is aimed at building on Arena's historical research platform.
Beacon also plans to associate global pharmaceutical partners in the drug discovery and early-stage development process.
Arena will have certain rights to compounds developed by Beacon and will be entitled to some of the latter’s future cash flows.
Arena has a few early- to mid-stage candidates in its pipeline targeting various therapeutic areas. For the development of its pipeline, the company has inked collaboration agreements with companies like Axovant (nelotanserin for central nervous system disorders; currently in phase II studies), Ildong (temanogrel for thrombotic diseases – phase I study ongoing) and Boehringer Ingelheim (preclinical development of candidates targeting a central nervous system receptor for psychiatric diseases).
Beacon will also assist Arena in the execution of the company’s proprietary pipeline programs, including the collaboration with Boehringer Ingelheim.
However, Arena currently has a Zacks Rank #4 (Sell). The company is facing a tough time now, with its only approved product Belviq, approved for the treatment of obesity, recoding lackluster sales. Belviq was launched in Jun 2013. However, the drug is yet to gain approval in the EU, where the marketing application was withdrawn in 2013. Companies like Novo Nordisk (CO:NOVOb) and Orexigen have already got a head start in the EU, where their obesity treatments were approved in 2015. Moreover, Arena has decided to drop certain lifecycle management programs on Belviq.
Stocks to Consider
Some better-ranked stocks in medical genetics sector include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Anika Therapeutics Inc. (NASDAQ:ANIK) and Cambrex Corporation (NYSE:CBM) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
ARENA PHARMA (ARNA): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
Original post
Zacks Investment Research
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.